
COVIDã¯ã¯ãã³ã®ä»åŸã®èšåºè©Šéšããã¹ãŠã¹ãããããFDAã®èšç»ãWHOãæ¯æŽ
å èšäºã¯ãã¡ã/Original article here
ç·šééšæ³šïŒç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ææ¥6æ28æ¥ããã¡ã€ã¶ãŒç€Ÿãšã¢ãã«ãç€Ÿãæ°ããã¯ã¯ãã³ã®èšåºè©Šéšãè¡ãããCOVID-19 mRNAã¯ã¯ãã³ãæ°žä¹ ã«ãå補é ãã§ããããã«ããèšç»ããæªæ¥ã®æ çµã¿ãã«ã€ããŠã®æç¥šãè¡ãäºå®ã§ããããããã¯ãªãã¯ããŠãFDAã« "Future Framework "ã«å察祚ãæããããäŒããŠãã ããã
ã¯ããã« FDAã¯åžžã«è£œè¬äŒç€Ÿã®ããã«ã²ãŒã ãæäœãã
éææ¥ã®ååŸé ããFDAã¯ã6æ28æ¥ç«ææ¥ã«ãªãŒãŠã§ã«çãªãå°æ¥ã®æ çµã¿ããæç¥šããã¯ã¯ãã³ããã³é¢é£çç©åŠç補å€è«®åå§å¡äŒïŒVRBPACïŒäŒè°ã®è°é¡ãçºè¡šããã
ãããŠåææ¥ã®æãFDAã¯ãå°æ¥ã®COVID-19泚å°ã«é¢é£ããŠãæã ãç¥ã£ãŠãããããªç§åŠãçµãããããã®èšç»ã«é¢é£ããèª¬æææžãçºè¡šããã(ãããã®ææžã«ã€ããŠç§ã«èŠåããŠããããåªç§ãªJames Roguskiã«å€§ãã«æè¬ãã)ã
ãã®èšäºã§ã¯ãèª¬æææžã®å 容ãäŒè°ã§èµ·ãããããªããšããããŠããã«å¯ŸããŠäœãã§ãããã説æããã
FDAã®ãFuture Frameworkãèª¬æææž
ãã®å ±åæžã¯ã1.5è¡ééã§18ããŒãžã®ããã¹ãã§ãããã19ã®åèæç®ãããããã®ãã¡9ã€ã¯ãã¬ããªã³ããCDCã®ç€Ÿå å ±Morbidity and Mortality Weekly ReportïŒMMWRïŒã®ãã®ã§ãã€ãŸãæ»èªãåããŠããªããã®ã§ããã
The Narrative(TM)ã®çã®ä¿¡å¥è ãªããæ°æéã§ãããæžãäžããããšãã§ããã ãããCOVID-19泚å°ã®å°æ¥å šäœãããã®èŠæãåãã®åŠéšçåãè«æã«åºã¥ãããã®ã¯ãçæ°ã®æ²æ±°ãšããèšãããããªãã
ç§ãäºæž¬ããããã«ã4æ6æ¥ã®äŒè°ã¯ãäœã®çµè«ã«ãéããªãæ¢çŽ¢çãªæåã®äŒè©±ãšããŠæç€ºãããã«ããããããããå°æ¥ã®æ çµã¿ãã¯ãä»FDAã«ãã£ãŠãå®äºããååŒãæ¢æäºå®ãé©åãªå®å šæ§è©Šéšã䞻匵ããã®ã¯é ããããããšããæããªããã®ãšããŠæç€ºãããŠããã®ã§ããã
ãã®èª¬æææžã®æ žãšãªãäž»åŒµã¯æ»çšœã§ããïŒãšããããã倧éèæ®ºãæ°žä¹ ã«å¶åºŠåãã蚌æ ãé èœããèšç»ã§ãªããã°ãæ»çšœã§ãããïŒãäœã«æãã§FDAã¯ãã䞻匵ããŠããïŒå£èªäœã§è¡šçŸããŠããïŒã
ãã®COVID-19泚å°ã¯çŽ æŽãããåãããããæ¬åœã«å¥è·¡ã ãä¿¡ããããªãã»ã©å¹æçã ããªããšããå¹ãããšãïŒãããŒã¹ã¿ãŒãããã ãå®å šã«ããŒã ã©ã³ã ãã€ã¹ã©ãšã«äººã¯è人ãå©ãããããããªããšãã10é±éã®ããŒã¿ãŸã§æã£ãŠããããã以äžã®èšŒæ ã¯ãªãã ããïŒ
ãŸãããå¹ãããšããæå³ã«ããããŸããããã®æ³šå°ã¯ææãäŒéãå ¥é¢ãæ»äº¡ãæ¢ãããã®ã§ã¯ãããŸããããã®ããã«ç§ãã¡ã¯æ³šå°ãèš±å¯ããŠããã®ã§ããããã®ãŠã€ã«ã¹ã¯å€ç°ãæ©ããå€ç°ãèµ·ãããšã¯èª°ãèšã£ãŠããªãã
ã ããããããã®æ³šå°ã¯å補é ãããªããã°ãªããªãããæã ã¯è£œè¬äŒç€Ÿã«é©åãªèšåºè©Šéšãè¡ãããæ±ããããšã¯ã§ããªãããªããªãããããã®æ³šå°ã¯çŽ æŽãããåããããããšããã§ã«åãã£ãŠããããã ïŒãã€ã³ã1åç §ïŒ!
説æäŒè³æã«ã¯æåéãããæžãããŠããã
ãã¯ã¯ãã³æ ªæ§æã®æ±ºå®ãç®çãšããæ¹å€ã¯ã¯ãã³ã®è©äŸ¡ã¯ãã¯ã¯ãã³è£œé ãèšåºå¹æè©äŸ¡ã«é¢ããæéçå¶çŽãããäž»ã«æ¯èŒå ç«åæ§ããŒã¿ã«äŸåããå¿ èŠããããŸããã
ãåããããã ããã ãããïŒè©äŸ¡ã¯ããæéçå¶çŽãã®ãããå®éã®å¥åº·äžã®ææä»¥å€ã®ææšã«ãé Œãå¿ èŠããããïŒããã§ã¯æ±ºå®ããŠããªãïŒã
ãããç§åŠã ïŒ
ModernaãPfizerãNovavaxã¯ãã¹ãŠCOVID-19ã®æ¹è¯å泚å°ãéçºããŠããŸãããããã圌ãã¯FDAãå¥åº·äžã®ææãèŠãããšããªãããšãç¥ã£ãŠããã®ã§ãæäœåå¿ã倧ããããããã«å€å€§ãªåªåãæã£ãŠããã
ãã¡ã€ã¶ãŒã¯ãå®å šæ§ã®æžå¿µããã以åã¯ãã以äžã®æäžéãåŠå®ããŠããã«ããããããã2åã®åŒ·ãïŒ30mcgã§ã¯ãªã60mcgã®mRNAïŒããã¹ããããããã§ãæäœã¬ãã«ãäžæ°ã«äžæããã®ã§ãã
ããããVRBPACã¯4æ6æ¥ã«ãé²åŸ¡ã®çžé¢é¢ä¿ã¯ç¥ãããŠããªãïŒã€ãŸããæäœã¬ãã«ã§ã¯èª°ãå ç«ãç²åŸãããã¯ããããªãïŒã®ã§ããããã®æäœæž¬å®ã¯å»åŠçã«ç¡æå³ã§ããããšãèªããã®ã ã
ãŸãšããªäººãªããå ç«åå¿ãä¿é²ãããã°ãæå®³äºè±¡ãä¿é²ãããããšãã§ããããšãçè§£ããŠããããããããæªæ¥ã®æ çµã¿ãã¯ã補è¬äŒç€Ÿãèšåºè©Šéšãå®å šã«çç¥ããããšãå¯èœã«ããŸãã
ããã«ããããã®äŒæ¥ã¯ãã¹ãŠããªãªãžãã«ã®ãªãã¯ãã³æ ªïŒBA.1ïŒããã§ã«ä»ã®äºçš®ïŒBA.4ãšBA.5ïŒã«åã£ãŠä»£ããããã«ããããããããããæšçãšããæ³šå°ãéçºããŠããã
FDAããããã®äŒæ¥ã¯ãBA.1ãã¿ãŒã²ããã«ããæ³šå°ã¯ããã以éã®äºçš®ã«ãæå¹ã§ãããšäž»åŒµããŠããããå®éã®å¥åº·ããŒã¿ãå šããªã以äžãã©ã䞻匵ããã°ããã®ãããããªãã
FDAã®ãFuture Frameworkãèª¬æææžã«ã¯ãªãèšèã
ãªãªãžãã«æåã®çœªã
æäœäŸåæ§å¢åŒ·,
ããªãªã³ç
,
å¿çç
VAERS
æå®³äºè±¡ããŸãã¯
å¯äœçš
ã€ãŸããFDAã¯æåéããææªã®ã·ããªãªã®å¯èœæ§ã«ã¯äžåç®ãåããŠããªãã®ã§ãã
æªæ¥ãã¬ãŒã ã¯ãŒã¯ã¯ãCOVID-19ã¯ã¯ãã³ããã°ã©ã å šäœããç§åŠã§ã¯ãªãéæ³ã®ãããªæèã«åºã¥ãããèšç»ãªã®ã§ãã
6æ28æ¥ïŒç«ïŒã®VRBPACããŒãã£ã³ã°ã§èµ·ãããããªããš
ã«ã«ãã«ãäºæž¬ã§ããã®ã¯ã圌ããèæ¬ã«åŸã£ãŠè¡åããåã人ç©ãäœåºŠãäœåºŠã䜿ã£ãŠããããã§ãã
æåã®ãã¬ãŒã³ããŒã·ã§ã³ã¯ãCDCã®ã¹ã¿ããã§ããHeather Scobieã«ãã£ãŠè¡ãããäºå®ã ã圌女ã¯ãããã6æ7æ¥ã®VRBPACããŒãã£ã³ã°ã®ã¹ã©ã€ãã䜿ããæåã®ã¹ã©ã€ãã®æ¥ä»ãå€ãããªãã¯ãã³ãç±³åœã§äž»æµã®SARS-CoV-2äºçš®ã«ãªã£ãããšã瀺ãããã«å°ãæŽæ°ããã ããã
èŠæšã¯ãããããã¿ã€ããã®æŠæŒ¢ç ç©¶æã®ãªãŒã¯åãã¢ã«ãã¡åãããŒã¿åããã«ã¿åãã¬ã³ãåã«å¯Ÿããã¯ã¯ãã³æ¥çš®ã«ã¯æå³ããªãããªããªãä»ã¯ãã¹ãŠãªãã¯ãã³åã ããã ããšãããã®ã§ãã
圌女ã¯ãã¢ãããšãã¡ã€ã¶ãŒãBA.1åã®ãªãã¯ãã³ãæšçãšããäºé²æ¥çš®ãèšèšããŠãããçŸåšãã®åã¯è¡°éããBA.4ãšBA.5ã«åã£ãŠä»£ããããŠãããšããããšã¯æããŠãããŸãããããã«ããããã®æ³šå°ãã¯ã¯ãã³ã«ããé²åŸ¡ãåé¿ããå€ç°äœã®é²åãä¿ããŠãããšããäºå®ã«ã¯è§Šããªãã
Scobieå士ã«ç¶ããŠãããäžäººã®CDCã¹ã¿ãããRuth Link-Gellesãããããã仿ãã§ã«è¡ããã4ã€ã®VRBPACãš4ã€ã®ACIPäŒè°ããã®ã¹ã©ã€ããããã®äžã€ãã»ãããè¿ããŠãæäººã«ãããCOVID-19ã¯ã¯ãã³ã®æå¹æ§ã«ã€ããŠè°è«ããããšã§ããããRLGãç§ãåããããã®ã¯ã圌女ãå šãç¡é¢å¿ã ããã ã
圌女ã¯ããããã®äŸ¡å€ã®ãªã泚å°ã®åŠå®çãªæå¹æ§ã次ã ãšã¹ã©ã€ãã§ç€ºãããVRBPACãå°ç¶ã«ã¯ã¯ãã³ãšæžããŠãããã®ã¯äœã§ãæ¿èªããããšãç¥ã£ãŠããã®ã§ãæ°ã«ããªãã®ã ãRLGã®ãã¬ãŒã³ã¯ãããŒã¿ããã®ãŸãŸäœ¿ãããšãã圢ã ãã®è©Šã¿ã§ããã圌女ã®ããŒã¿ã¯ãã¹ãŠå³åº§ã«èšæ¶ããæ¶ããäºåºŠãšèªãããããšã¯ãããŸããã
次ã«ãã«ã«ãã«ãéžãã ã¹ããŒã«ãŒã¯ãããŒã¹ã«ãã©ã€ã倧åŠã®ãžã£ã¹ãã£ã³ã»ã¬ãã¹ã©ãŒã§ãããã¬ã¹ã©ãŒå士ã¯è¿å¹Žãã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ãã10ä»¶ã®å©æéãåŸãŠããïŒåœŒã®å±¥æŽæžã®26ããŒãžãã30ããŒãžãåç §ïŒã
ãããŠãNIHããããŒã»ãã¡ãŠãã®æå±ããåœç«ã¢ã¬ã«ã®ãŒã»ææçç ç©¶æïŒNIAIDïŒããã10ä»¶ã®å©æéãåŸãŠããã
ããèãããšãã¬ã¹ã©ãŒå士ããèªãéšãïŒTMïŒãæ¹å€ãã確çã¯ã©ã®ãããã ãããïŒãŒãã§ãã
ã²ã€ããšãã¡ãŠãã¯æåéããCOVID-19ã®å°æ¥ã®ç«åŠã«ã€ããŠã©ãèããã¹ããã«ã€ããŠãäŒè°ã®äžã§éšäžã«ã¢ããªã³ã°ããããŠããã®ã§ãã
ã²ã€ãã¯2017幎ã«ãã¢ããªã³ã°ãæ¿çã®ç¬ãæ¯ãåã尻尟ã§ããããšãçè§£ãããã以æ¥ãããã«å€é¡ã®æè³ãããŠããŸãã
ã¬ã¹ã©ãŒå士ã¯é ã®ãŠã£ãºãããã€ãŸå ãŸã§å©ççžåã«æµžãã£ãŠãã--圌ã¯ãã®å§å¡äŒã®100ãã€ã«ä»¥å ã«å ¥ããªãã¯ãã --ã«ãããããããFDAã¯ãã®ç·ããå©ççžåã®æŸæ£ãèŠæ±ããããšãããªãã ããã
ã«ã«ãã«ã¯ã«ã«ãã«ã ã
çãäŒæ©ã®åŸãã¢ãã瀟ã®ã¹ãã£ãŒãã³ã»ããŒã°ç€Ÿé·ããã¡ã€ã¶ãŒç€Ÿã®ããŒãã»ã¹ã¯ã³ãœã³å¯ç€Ÿé·ãããããã¯ã¹ç€Ÿã®ã°ã¬ãã°ã»ã°ã¬ã³ç€Ÿé·ãã圌ãã®æ¹è¯åCOVID-19泚å°ãããã«çŽ æŽããããã説æãããã圌ãã¯ããé©åãªèšåºè©Šéšãè¡ãæéããªããšäž»åŒµããã ããã
圌ãã®ããŒã¿ã¯ã©ããå°éå®¶ã«ãã審æ»ãåããŠããªãããããã¹ãŠæ¶ç©ºã®äœã話ãã€ãŸã95ïŒ ãã100ïŒ ã®æå¹æ§ãå®å šã«ä¿¡å¿µã«åºã¥ããŠããã
ãããŠãFDAã¯2人ã®ã¯ããŒãµãŒãé£ããŠããïŒãããæ¬åœã«é¢çœããšããã ïŒã
ãªãŒã¹ãã©ãªã¢ã»ã¡ã«ãã«ã³ã®äžçä¿å¥æ©é¢ïŒWHOïŒå ±åã»ã³ã¿ãŒã®ãã£ã¬ã¯ã¿ãŒã§ããKanta SubbaraoãããWHOããã®ã¯ã¯ãã³æ ªæ§æã®èå¯ããçºè¡šããŸããTAG CO-VAC "ã§ãã
ç§ã¯ã€ãæšæ¥ãŸã§ïŒãã®èšäºãæžãå§ãããŸã§ïŒããã®ãæªæ¥ã®æ çµã¿ãå šäœããå®ã¯WHOããçºä¿¡ãããŠããããšãçè§£ããŠããŸããã§ããããã«ïŒã¡ãªã³ãã»ã²ã€ã財å£ã¯ãWHOãžã®æå€§ã®ãã©ã³ã¿ãªãŒæ åºè ã§ãããã€ãŸããã²ã€ãããã®èå± ãæŒåºããŠããã®ã ããã
ã²ã€ãã¯WHOã«ãããã³ãŒãŒã®ã³ã³ãµã«ãã£ã³ã°äŒç€Ÿã䜿ãããã«èŠæ±ããŠããã®ã§ãããã¯ãããããããã³ãŒãŒã®äœæŠã§ãããïŒãããã³ãŒãŒã¯è£œè¬äŒç€Ÿãšãä»äºãããŠããã®ã§ãããã¯å€§ããªå©ççžåã«ãªããŸãïŒãNaomi Wolfãææããããã«ãWHOã®é¢äžã¯ããã®ããã»ã¹ã«å¯Ÿããäžåœå ±ç£å ã®åœ±é¿åã«ã€ããŠãåä»ãªåé¡ãæèµ·ããŠããã
1æã®æç¹ã§ãWHO/ã²ã€ã/ãããã³ãŒãŒæ¿æš©ã¯ããã®æ³šå°ãã²ã©ããã®ã§ããããšã«æ°ã¥ããŠããããããæ©äŒã«ããã«æš©åãšæ¯é åãæã«å ¥ããããšèããã®ã ã
WHOã¯COVID-19ã¯ã¯ãã³çµæã«é¢ããæè¡è«®åã°ã«ãŒãïŒTAG-CO-VACïŒãç«ã¡äžãã補è¬äŒç€Ÿã®è£œé ã³ã¹ããäžããå©çãæãªããããããªãåä»ãªå¥åº·ããŒã¿ãé¿ããããã«ãå é²åœå šäœã§ãããã®ãªãŒãŠã§ã«çãæªæ¥ã®æ çµã¿ãã宿œããããšã«ããã®ã§ããã
ç§ãã¡ãFDAããç®ã«ãããã¹ã³ãã«ãªãŒã¯ãããã¡ãã»ãŒãžã¯ããã¹ãŠTAG-CO-VACãæåã«éçºããçºè¡šãããã®ã§ãã
WHOã«å ¥ãåãKanta Subbaraoã¯14幎éNIAIDã«ããã®ã§ã圌女ã¯Fauciã®å¿ å®ãªéšäžã§ãã
圌女ã¯4æ6æ¥ã®VRBPACäŒè°ã®ã¹ã©ã€ãã磚ãäžããCOVID-19ã¯ã€ã³ãã«ãšã³ã¶ã«äŒŒãŠãããèæ ªã®éžæã¯äžççã«èª¿æŽãããªããã°ãªãããå€äŸ¡ã®New & Improved(TM) COVID-19 Shots Now with OmicronïŒ(TM)ããã®æ¥ãæããã³ãããã¯ãçµãããããšäž»åŒµããã§ãããã
圌女ã®äž»åŒµã¯ã©ããçå®ã§ã¯ãªãã ããããã«ã«ãã«ãèšããããããšã§ãããããã¯äœãããè³éåã®ãã人質ãããªã«è¿ãã®ã§ããã®éãã«ãªãã®ã ããã
æåŸã«FDAã¯ããšã»ããã»ãµã ãšãµã ã»ãšãªãªãããæãåããããããªãžã§ãªãŒã»ãŠã£ã¢ãŒãç»å Žãããäºå®ã§ãã圌ã¯ã4æã®ã¹ã©ã€ããå°ãæŽæ°ããã€ã³ãã«ãšã³ã¶æ ªã®éžæããã»ã¹ïŒå€±æïŒã«ã€ããŠããããŠãããããã«ã¢ãã«ã§ããã¹ããã«ã€ããŠãå§å¡äŒãããŸããèµ·ãããŠäœã«ã§ãåæããããã«ãªããŸã§ããã©ãã芳å¯ãç¹°ãè¿ãè¡ãã ããã
å ¬åŒã«æç¥šããã質åã¯ã以äžã®éãã§ãã
ãå§å¡äŒã¯ãç±³åœã«ãããCOVID-19ããŒã¹ã¿ãŒã¯ã¯ãã³ã«SARS-CoV-2ãªãã¯ãã³æåãå«ããããšãæšå¥šãããïŒã
ãã®èšèã¯å€ããææ§ã«ãããããŒã¹ã¿ãŒãä»ã®åžå Žã§ããæ¹è³ªãããæ³šå°ã§ã¯ãªããããŒã¹ã¿ãŒãšåŒã¶ããšã§ãæ°ããªèšåºè©Šéšãè¡ãããªããªãã
å€ã®éã«ã以åã®ããŒãžã§ã³ã®æ³šå°ã¯éãã«åžå Žããæ€éããèšåºè©Šéšãã¹ãããããæ¹è¯å泚å°ãå¯äžã®éžæè¢ãšãªããã€ãŸããããã¯FDAã®ã€ã¿ããã£ãã§ãããCOVID-19泚å°ã®èšåºè©ŠéšãäºåºŠãšè¡ããªããšããæ»ãå°ãæ»ãéããæ¹æ³ãªã®ã ã
ãããFDAãèªåãã¡ãããããšããŠããããšãã¯ã£ããèšãã°ãæŽåãèµ·ããã ããã
äœããã¹ãã
ç§ãã¡ã¯çŽ24æéããè¡åã§ããªãã®ã§ãçŸå Žã«ãã¹ãŠãå§ããŸããã
FDAããæªæ¥ã®æ çµã¿ããæåŠãããã¹ãŠã®æ¹è³ªãããCOVID-19ã·ã§ãããé©åãªããèšåºè©Šéšãçµãªããã°ãªããªãããšãç€ºãæ£åŒãªã³ã¡ã³ããregulations.govã®ãŠã§ããµã€ãã«æåºããŠãã ããã蚎èšäºä»¶çªå·ã¯FDA-2022-N-0905ã§ãã
ãã®èšŽèšèšé²ã¯ã6æ27æ¥ïŒæïŒå€ãæ±éšæé11:59ã«çµäºããŸãããããã¯ãªãã¯ããŠregulations.govã®ãŠã§ããµã€ãã®é¢é£ããŒãžã«ç§»åããå·Šäžé ã«ããéãã³ã¡ã³ããã¿ã³ãæ¢ããŸãã
FDAã¯æåºãããã³ã¡ã³ãã®æ°ã«ã€ããŠåãã€ããŸãããç§ãã¡ã¯ããã«ã€ããŠèšŽèšãèµ·ãããŠããã®ã§ãããå€ãã®ã³ã¡ã³ããæåºã§ããã°ïŒåœŒãã¯ãã®åŸé ããŸããïŒãç§ãã¡ã®ã±ãŒã¹ã«ãšã£ãŠããè¯ããã®ã§ãã
ããã«ã以äžã«FDA/VRBPACã§ãã®ä»¶ã«é¢ããŠçºèšæš©ãæã€å šå¡ã®ã¡ãŒã«ã¢ãã¬ã¹ãæ²èŒããŸãããã®ããã»ã¹ã«é¢ããç§ãã¡ã®èããæžå¿µã圌ããšå ±æããããšã¯ãç§ãã¡ã®æš©å©ã§ãããèªèº«ã®äœéšè«ãã以äžã®ã¡ãã»ãŒãžãã³ããŒïŒããŒã¹ãããŠãã ããã